Leerink reiterates Outperform on OmniAb stock after partner trial fails By Investing.com

OmniAb reported Q4 FY2025 revenue of $8.4M, down 22.2% year-over-year, but delivered an EPS of -$0.11 versus a -$0.13 consensus and cut operating expenses by 9.7%. Partner Immunovant’s Phase 3 failure of batoclimab in thyroid eye disease did not change analyst views—Leerink reiterated an Outperform with a $10 PT and maintained $25–$30M guidance, while Benchmark ($4 PT), Stifel ($9 PT) and Truist (Buy) also stayed positive, citing IMVT-1402 as the primary near-term catalyst with >$100M in potential milestones.

Analysis

A partner clinical setback often produces a two-step market reaction: immediate sentiment-driven de-risking of the partner equity and concurrent re-pricing of the platform owner as investors re-evaluate optionality. The platform owner’s market value is driven more by the probability-weighted pipeline of future milestone receipts and royalty streams than any single asset, so a single negative readout should compress implied probabilities but not eliminate structural value—unless it exposes a concentrated milestone trigger or counterparty solvency risk.

Second-order effects matter: partners will re-prioritize capital and regulatory bandwidth after a negative readout, which lengthens expected timelines for downstream payout and increases the chance milestones slip into later dates (reducing NPV materially at typical discount rates). That recalibration also raises partner concentration risk premiums for platform licensors — meaning acquisition interest or milestone sell-downs could become the marginal source of value realization rather than organic royalty accruals.

From a funding and volatility perspective, small- to mid-cap biotech names tied to binary readouts will see elevated implied vols and asymmetric tail risk for quarters after the event; equity financing windows can narrow, making contingent-value deals and milestone accelerators likelier. Conversely, the platform owner with multiple partner programs stands to gain from any positive deviance in the largest remaining program: a successful registrational readout becomes a high-impact, multi-quarter derisking event that can re-rate the entire entity.

Key reversal scenarios to monitor are (a) a partner pivot that reassigns the same mechanism to another asset (accelerating milestones), (b) an announced milestone carve-out or sale that crystallizes value, or (c) widening credit stress at major partners that turns a clinical disappointment into a nearer-term solvency story. Time horizons: price dislocation runs days–weeks; fundamental re-rating runs 6–24 months around next registrational or financing events.

Key Decisions for Investors

• Long OABIW via defined-risk options (buy 9–15 month call spreads) to capture platform optionality into the partner readout window; target asymmetric payoff of ~2x–3x if next registrational event is positive, stop-loss at 30% of premium to limit theta decay exposure.
• Short IMVT equity or buy 3-month ATM puts to capture near-term binary downside from investor de-risking; size as catalyst trade (small position), target 30%–60% downside within 1–3 months, exit or hedge if implied volatility rises >50% from baseline.
• Pair trade: long OABIW / short IMVT in a 1:1 dollar-neutral ratio to isolate platform vs partner binary risk over 3–12 months; rebalance after any partner financing or regulatory update that changes cash runway assumptions.
• Event-driven special: if market-implied probabilities compress implied value below conservative NPV of non-dependent milestones, consider buying OABIW equity ahead of potential milestone-sale or partnering announcements with a 12–24 month horizon; hedge by buying put protection sized to limit downside to ~25% of position value.